A Phase 1 interventional study of QLC7401 injection and RBD7022 injection in Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.
Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 47th largest by planned enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 in phase 1, reaches primary completion later than 4 of the 16 other live ones, and was the 54th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18–85
Novartis Pharmaceuticals · Sites in China, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 20 more countries
Ages 6–11
Hasten Biopharmaceutical Co., Ltd. · Sites in China
Ages 18+
Stephen Nicholls · Sites in China, Australia, India and 6 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 8 · Phase 3 27 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 207 across the 53 interventional studies, 924 across the 6 observational. Of the 39 that completed or were terminated, 9 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 59 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 1 study filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypercholesterolemia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07930507Phase 3AstraZenecaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients | 2027-10-11 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05325034Stephen NichollsGuideline Oriented Approach To Lipid Lowering In Asia-Pacific | 2026-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Hypercholesterolemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the pharmacokinetics and pharmacodynamics behavior of the two formulation of QLC7401 injection to further evaluate the effect of the production site change.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: QLC7401 injection
Drug: RBD7022 injection
QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.
RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.
Cmax
Maximum plasma concentration of QLC7401 and active metabolites.
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
AUC
Area under the concentration-time curve of QLC7401 and active metabolites.
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
Tmax
Time of maximum observed concentration of QLC7401 and active metabolites..
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
t1/2
Terminal elimination half-life of QLC7401 and active metabolites.
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
CL/F
Apparent total clearance of the drug from plasma after oral administration of QLC7401 and active metabolites.
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
VZ/F
Apparent volume of distribution after oral administration of QLC7401 and active metabolites.
Time frame: 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post dose
Start is estimated for Jul 2025; primary completion for Jan 2026, 6 months later.
Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 6 months is below that.
Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QLC7401
Qilu Pharmaceutical Co., Ltd. →